Related Experiment Video

Updated: Jun 3, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Multifactorial nature of tumor drug resistance

G I Solyanik1

  • 1RE Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of NAS of Ukraine, Kyiv, Ukraine. gis@onconet.kiev.ua

Experimental Oncology
|March 16, 2011
PubMed

Insights

Tumor drug resistance (TDR) is a complex challenge in cancer treatment. Beyond single-cell changes, TDR involves multicellular interactions and the tumor microenvironment, impacting drug efficacy.

Area of Science:

  • Oncology
  • Cancer Biology
  • Pharmacology

Background:

  • Tumor drug resistance (TDR) is a significant barrier to effective cancer therapy.
  • Historically, TDR was attributed to intracellular mechanisms like gene mutations or epigenetic alterations.
  • Emerging evidence highlights the role of multicellular interactions and the tumor microenvironment in TDR.

Purpose of the Study:

  • To analyze the multifactorial nature of tumor drug resistance.
  • To examine pharmacokinetic and pharmacodynamic aspects of TDR mechanisms.
  • To discuss strategies for overcoming TDR and enhancing cancer treatment efficacy.

Main Methods:

  • Review and analysis of existing data on TDR mechanisms.
  • Examination of pharmacokinetic and pharmacodynamic principles related to TDR.
  • Discussion of therapeutic strategies to combat TDR.

Main Results:

  • TDR is influenced by both intracellular factors and extracellular components, including cell-cell interactions and the tumor microenvironment.
  • Limited drug penetration into tumor tissue is a critical factor contributing to TDR.
  • Understanding these multifactorial aspects is crucial for improving clinical trial outcomes.

Conclusions:

  • TDR is a complex phenomenon involving multiple biological levels.
  • Addressing TDR requires considering not only cellular but also microenvironmental and pharmacokinetic factors.
  • Developing novel therapeutic approaches targeting these diverse mechanisms is essential for improving cancer treatment outcomes.

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...